We conducted a serial cross-sectional study to evaluate the use of PET imaging among commercial insurance beneficiaries with prostate cancer using administrative claims from deidentified Blue Cross ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Some high-grade prostate cancers, such as intraductal carcinoma of the prostate, are not clearly visible on PSMA PET. For patients with intraductal carcinoma of the prostate (IDC-P), prostate-specific ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...

Application error: a client-side exception has occurred (see the browser console for more information).